Recent studies indicated that tumor-reactive CD4+ T cells have a potential to up-regulate expression of MHC class-II on melanoma B16 cells, and thereby reject the cells by an MHC-II restricted mechanism in a mouse model [1], [2]. The gene discussed is CD4; the disease is neoplasm.